Buy Evolent Health
Amount
Latest price
$11.765
(£1.00 = $1.365)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$1.384B
P/E ratio
-9.66
EPS
-$1.22
Beta
0.82
Dividend rate
N/A
Dividend yield
N/A
About
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
CEO
Mr. Seth Blackley
Employees
4,500
Sector
Services
Company HQ
ARLINGTON, United States of America
Website
News
Evolent Health (EVH) Stock Jumps 6.9%: Will It Continue to Soar?
Evolent Health (EVH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON , June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M.
Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Jack Doney - UBS Matthew Gillmor - KeyBanc Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Jeff Garro - Stephens Kyle Aikman - JPMorgan Matthew Shea - Needham Constantine Davides - Citizens Charles Rhyee - TD Cowen Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earning Conference Call for the First Quarter Ended March 31, 2025. As a reminder, this conference call is being recorded.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe, Emma vs Moneyhub.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.